en · de · es · fr · pt
liraglutide-notes.peptides6608.com › Data › �ƒŒ景与分子特征 — What the Evidence Shows

�ƒŒ景与分子特征 — What the Evidence Shows

By Editorial Desk · published 2026-03-04 · last reviewed 2026-03-25 · Data

ghrelin receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-03-25. Where a claim depends on a specific study, the study is described rather than over-claimed.

背景与分子特征

Ipamorelin 是一种合成五肽,序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2,分子式 C38H49N9O5,游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素(GHS)家族,作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道,设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。

在 GHS 家族中,早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放,并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性,对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同,而完整的分子解释仍有待补充。需要区分的是,选择性是研究观察中的相对程度,并非绝对界限。

从用途定位看,ipamorelin 目前主要以研究用肽的身份被讨论,未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用,不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小,因此对其效应强度与一致性的描述应保持谨慎。

Ipamorelin Background and Receptor Selectivity

At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.

Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.

Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.

Ipamorelin at a glance

PropertyValueNotes
分子式C38H49N9O5五肽,C 端酰胺化
分子量约 711.85 g/mol游离碱形式
外观白色至类白色冻干粉研究用材料的常见形态
溶解性溶于水及 DMSO 等极性溶剂建议现配现用
储存温度-20 °C 或更低干燥、避光、限制冻融次数

Background And Receptor Mechanism

Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.

At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.

Related pages on this site

Handling, Stability and Analytical Verification

Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.

Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.

Notes from published material

Financial response The primary financial restitution paid by UCC was negotiated in 1989, when the Indian Supreme Court approved a settlement of US$470 million (₹1,055 crore; equivalent to $1.03 billion in 2024). This amount was immediately paid by UCC to the Indian government. The company states that the restitution paid "was $120 million more than plaintiffs' lawyers had told U.S. courts was fair" and that the Indian Supreme Court stated in its opinion that "compensation levels under the settlement were far greater than would normally be payable under Indian law." In the immediate aftermath of the disaster, Union Carbide states on its website that it donated $2 million to the Indian prime minister's immediate disaster relief fund on 11 December 1984. The corporation established the Employees' Bhopal Relief Fund in February 1985, which raised more than $5 million for immediate relief. According to Union Carbide, in August 1987, they made an additional $4.6 million in humanitarian interim relief available. Union Carbide stated that it also undertook several steps to provide continuing aid to the victims of the Bhopal disaster, including the sale of its 50.9% interest in UCIL in April 1992 and establishment of a charitable trust to contribute to the building of a local hospital. The sale was finalised in November 1994. Construction began in October 1995 and the hospital opened in 2001. The company provided a fund of around $90 million from sale of its UCIL stock. In 1991, the trust had amounted to approximately $100 million.

However while THC's pharmacodynamic tolerance may limit the maximal effects of certain drugs, evidence suggests that this tolerance mitigates undesirable effects, thus enhancing the drug's therapeutic window. Recently, it has been shown that THC is also a partial autotaxin inhibitor, with an apparent IC50 of 407 ± 67 nM for the ATX-gamma isoform. THC was also co-crystallized with autotaxin, deciphering the binding interface of the complex. These results might explain some of the effects of THC on inflammation and neurological diseases, since autotaxin is responsible for LPA generation, a key lipid mediator involved in numerous diseases and physiological processes. However, clinical trials need to be performed in order to assess the importance of ATX inhibition by THC during medicinal cannabis consumption.

For laboratory quantities, up to 40 are possible. To prepare larger peptides, individual fragments are first produced and purified, and then combined to the final molecule by liquid phase synthesis. Thus, for the production of Roche's anti-AIDS drug Fuzeon (enfuvirtide), three fragments of 10–12 amino acids are first made by solid-phase synthesis and then linked together by liquid-phase synthesis. The preparation of the whole 35 amino acid peptide requires more than 130 individual steps. Microreactor Technology (MRT), used for process intensification, is a relatively new tool that is being developed at several universities, as well as fine chemical companies, such as Bayer Technology Services, Germany; Clariant, Switzerland; Evonik-Degussa, Germany; DSM, The Netherlands; Lonza, Switzerland; PCAS, France; and Sigma-Aldrich, US. The lattermost company produces about 50 fine chemicals up to multi-kilogram quantities in microreactors. From a technological point of view, MRT, or continuous flow reactors, represents the first breakthrough development in reactor design since the introduction of the stirred-tank reactor, which was used by Perkin & Sons when they established a factory on the banks of what was then the Grand Junction Canal in London in 1857, in order to produce mauveïne, the first-ever synthetic purple dye. For a comprehensive coverage of the subject see Micro Process Engineering. Reactions that have worked in microreactors include aromatics oxidations, diazomethane conversions, Grignards, halogenations, hydrogenations, nitrations, and Suzuki couplings.

== Procedure == The exact methods of this procedure are not standardized and vary considerably, for example the exact number and locations of the injections and the volume of the injected material. Before the operation, antibiotic prophylaxis may be given. The rectum is prepared with a phosphate enema at least 2 hours before the procedure. The procedure can be carried out under local anesthetic on an out patient basis, or with caudal epidural anesthesia, or with intravenous sedation, or under general anesthesia. Ultrasound guidance may be used during the injections, which is sometimes reported as being more effective than the surgeon simply palpating (feeling) and looking where to inject. The site of the bulking material can be inter-sphincteric (in the space between the IAS and the EAS), submucosal injections (under the mucosal layer, usually just above the dentate line), or within the IAS itself. Injection of the material can be by the different routes: transanal route, trans-sphincteric, intersphincteric, perianal route (going through the muscle complex) or transcutaneous route. As such, there are several different variations of injection location and route:

Sources: en.wikipedia.org

Further detail

=== Human β-casomorphin 7 === Structure: YPFVQPI Despite human beta-casein having a A2-like "P" after "I", human colostrum and early lactation-stage milk contains significant amounts of hBCM7. It is a much weaker opioid and the FVQ sequence renders it susceptible to further degradation.

== Energy release == The Q value is defined as the total energy released in a given nuclear decay. In beta decay, Q is therefore also the sum of the kinetic energies of the emitted beta particle, neutrino, and recoiling nucleus. (Because of the large mass of the nucleus compared to that of the beta particle and neutrino, the kinetic energy of the recoiling nucleus can generally be neglected.) Beta particles can therefore be emitted with any kinetic energy ranging from 0 to Q. A typical Q is around 1 MeV, but can range from a few keV to a few tens of MeV. Since the rest mass of the electron is 511 keV, the most energetic beta particles are ultrarelativistic, with speeds very close to the speed of light. In the case of 187Re, the maximum speed of the beta particle is only 9.8% of the speed of light. The following table gives some examples:

== History == Spontaneous vertebral artery dissection was described in the 1970s. Prior to this, there had been isolated case reports about carotid dissection. In 1971, C. Miller Fisher, a Canadian neurologist and stroke physician working at Massachusetts General Hospital, first noted the "string sign" abnormality in carotid arteries on cerebral angiograms of stroke patients, and subsequently discovered that the same abnormality could occur in the vertebral arteries. He reported the discovery in a paper in 1978.

=== Perceptual symptoms === Unawareness or denial of severity of condition (anosognosia), which may prevent some from seeking recovery Perception of self as heavier or fatter than in reality, i.e., body image disturbance Altered body schema, i.e., a distorted and unconscious perception of one's body size and shape that influences how the individual experiences their body during physical activities. For example, a patient with anorexia nervosa may genuinely fear that they cannot fit through a narrow passageway. However, due to their malnourished state, their body is significantly smaller than someone with a normal BMI who would actually struggle to fit through the same space. In spite of having a small frame, the patient's altered body schema leads them to perceive their body as larger than it is.

Whatever moral and religious interpretation one places upon it, the fall in Lynn clearly marked a turning point in [Eddy's] life, the moment when she began to take charge of her life... She herself consistently, and with increasing fervor and conviction, attributed that change to a new understanding of God's relation to the world, and to a new sense of her own special divine mission. Whether we label this delusion or revelation, the fact remains that the woman was fundamentally empowered, and that there was no external, material change to account for that increase of power.

Sources: en.wikipedia.org

Supporting material

== External links == "Astragalus membranaceus – Moench". Plants for a Future. "Astragalus membranaceus (FISCH. EX LINK) BUNGE – Fabaceae". Dr. Duke's Phytochemical and Ethnobotanical Databases. ARS / GRIN. Archived from the original on 2004-11-15.

The effects of 2C-B were reported by Shulgin to include sensory enhancement, brightened colors, visual richness, mental imagery, psychedelic visuals including kaleidoscopic and organic forms, sound distortion, increased appreciation of art and music, passivity, relaxation, emotional changes, euphoria, increased body awareness, tactile enhancement, feeling like waves of energy are flowing through oneself, feeling like one's body is flooded with orgasms, and sexual enhancement. He has succinctly described 2C-B as having "a luxury of sensory enhancement (visual, sexual, gustatory) with a minimum of introspective demands". The drug was one of his favorite psychedelics and one of his "magical half-dozen" most important psychedelic phenethylamines. At doses of 8 to 10 mg, 2C-B was described as consistently producing substantial sensory enhancement, but as not "superimposing hallucinogenesis" or as having "no hallucinogenic effects", with the state being described as quite distinct from that usually associated with psychedelics. It was also said to lack the lassitude that can be associated with psilocybin.

Polycondensation involves the formation of polymers through condensation reactions between different species, creating condensation polymers. With automated synthesis, General electric manufactured an approach for melt-polymerizations of BPA and diphenyl carbonate (DPC), using sodium hydroxide (NaOH) as the catalyst. Once the results were analyzed, it was shown that, by using an automated method of polymerization, the effect of varying the catalyst amount became more distinct and improved the reproducibility for the reaction. Furthermore, it demonstrated an increase within the homogeneity of the polymers in the microreactors.

Prolactin receptors are present in the mammillary glands, ovaries, pituitary glands, heart, lung, thymus, spleen, liver, pancreas, kidney, adrenal gland, uterus, skeletal muscle, skin and areas of the central nervous system. When prolactin binds to the receptor, it causes it to dimerize with another prolactin receptor. This results in the activation of Janus kinase 2, a tyrosine kinase that initiates the JAK-STAT pathway. Activation also results in the activation of mitogen-activated protein kinases and Src kinase. Human prolactin receptors are insensitive to mouse prolactin. Prolactin levels may be checked as part of a sex hormone workup, as elevated prolactin secretion can suppress the secretion of follicle stimulating hormone and gonadotropin-releasing hormone, leading to hypogonadism and sometimes causing erectile dysfunction. Prolactin levels may be of some use in distinguishing epileptic seizures from psychogenic non-epileptic seizures. The serum prolactin level usually rises following an epileptic seizure.

Sources: en.wikipedia.org

Frequently asked questions

Ipamorelin 与 GHRP-6 有什么不同?

两者都是 GHS-R1a 激动剂,但 ipamorelin 在研究中显示出更高的生长激素释放选择性。早期资料显示它对皮质醇、催乳素与食欲的刺激弱于 GHRP-6。这些差异是相对程度,而非绝对区分。

Ipamorelin 是已批准药物吗?

公开资料中它主要以研究用肽的形式出现,未获主要监管机构批准用于治疗。可得材料通常标注仅供研究使用。任何临床用途的宣称都缺少监管依据。

为什么它的序列含有非天然氨基酸?

序列中的 Aib 与 D-2-Nal 等非天然残基可提高对肽酶的抵抗能力,并影响受体结合的构象。这类修饰在合成肽设计中较为常见。它们也使常规氨基酸分析需要额外步骤才能确认序列。

Aib 残基起什么作用?

Aib 即 α-氨基异丁酸,是一种非蛋白质源氨基酸,其侧链为两个甲基。它在肽链中倾向于诱导螺旋构象并限制骨架的柔性。这种刚性被认为有助于抵抗蛋白酶切割。

Network